Edition:
United Kingdom

Apollo Endosurgery Inc (APEN.OQ)

APEN.OQ on NASDAQ Stock Exchange Global Market

6.30USD
19 Oct 2018
Change (% chg)

$0.05 (+0.80%)
Prev Close
$6.25
Open
$6.25
Day's High
$6.30
Day's Low
$6.25
Volume
484
Avg. Vol
15,057
52-wk High
$9.56
52-wk Low
$3.77

Summary

Name Age Since Current Position

Richard Meelia

69 2012 Chairman of the Board

Todd Newton

55 2014 Chief Executive Officer, Director

Stefanie Cavanaugh

53 2015 Chief Financial Officer, Secretary

Bret Schwartzhoff

46 2017 Vice President,North America Sales and Global Marketing

Christopher Gostout

67 2017 Chief Medical Officer

Rick Anderson

57 2013 Independent Director

Matthew Crawford

52 Independent Director

William McClellan

58 2014 Independent Director

R. Kent McGaughy

46 2012 Independent Director

David Pacitti

52 2017 Independent Director

Bruce Robertson

55 2008 Independent Director

Biographies

Name Description

Richard Meelia

Mr. Richard J. Meelia. Since July 2012, Mr. Meelia has served as the Chairman of our Board. From July 2007 until his retirement in July 2011, Mr. Meelia served as Chairman, President, and Chief Executive Officer of Covidien plc following its separation from Tyco International in June 2007. Mr. Meelia is a member of the Board of Directors of Haemonetics Corporation, for which he serves as Chairman, and ConformMIS, Inc. Mr. Meelia holds a B.A in Business from Saint Anselm College and an M.B.A. from Boston College. We believe Mr. Meelia's qualifications to serve on our Board include his extensive industry knowledge and experience as a chief executive within the medical device industry and his public company governance expertise.

Todd Newton

Mr. Todd Newton. is the Chief Executive Officer and Director of the company. Since July 2014, Mr. Newton has served as Chief Executive Officer and as a member of our Board. From April 2009 to June 2014, Mr. Newton served as Executive Vice President, Chief Financial Officer and Chief Operating Officer at ArthroCare Corporation, a medical device company. Mr. Newton holds a B.B.A. in Accounting from The University of Texas at San Antonio. We believe Mr. Newton's qualifications to serve on our Board include his extensive industry knowledge and experience as our Chief Executive Officer.

Stefanie Cavanaugh

Ms. Stefanie Cavanaugh is the Chief Financial Officer and Secretary of Apollo, Since March 2015. From 2014 to 2015, Ms. Cavanaugh provided advisory services to several healthcare companies. From 2010 to 2014, Ms. Cavanaugh served as Senior Vice President of Finance at Harden Healthcare, LLC, a provider of healthcare services for the long-term care industry, until its sale to Gentiva Health Services, Inc. Ms. Cavanaugh holds a B.B.A. in Accounting and Finance from the University of Texas at Austin and is a Certified Public Accountant.

Bret Schwartzhoff

Mr. Bret Schwartzhoff is the Vice President, North America Sales and Global Marketing of Apollo,Since December 2017. Mr. Schwartzhoff has served as previously holding positions of Vice President of U.S. Sales and Global Marketing from December 2016 to December 2017, and from December 2014 to December 2015, he served as Apollo's Vice President U.S. Sales. From 2011 to 2014, Mr. Schwartzhoff served as Vice President of Marketing, Sports Medicine at ArthroCare Corporation and Smith & Nephew plc, which acquired ArthroCare, both medical device companies. Mr. Schwartzhoff holds a B.S. in Business from Mankato State University and an M.B.A. from Wake Forest University

Christopher Gostout

Dr. Christopher J. Gostout, M.D. is the Chief Medical Officer of Apollo, Since January 2017. Between August 2013 and December 31, 2016, Dr. Gostout served as a consultant to Apollo. From 1983 to 2016, Dr. Gostout served in the Mayo Clinic in the Division of Gastroenterology and Hepatology. From 2005 to December 2016, he maintained a joint appointment in the Department of Surgery. In July 2000, he became a Professor of Medicine in the Mayo Clinic College of Medicine and the Director of the Developmental Endoscopy and Research Unit in 1998. Dr. Gostout holds a B.S. in Biology from Villanova University and a M.D. from the State University of New York Downstate Medical Center.

Rick Anderson

Mr. Rick Anderson is the independent director of the company, Since October 2013, Mr. Anderson has served as a member of our Board. Since 2008, Mr. Anderson has served as a Managing Director at PTV Healthcare Capital, a venture capital and private equity firm specializing in the healthcare and life sciences industries. Mr. Anderson is a member of the Board of Directors of ConvaTec Group Plc. In 2014, Mr. Anderson was a director of Intersect ENT, Inc. Mr. Anderson holds a B.B.A. in Marketing from Mississippi State University. We believe Mr. Anderson's qualifications to serve on our Board include his extensive industry knowledge and experience and medical device commercial expertise.

Matthew Crawford

Mr. Matthew S. Crawford is the independent director of the company. Since May 2006, Mr. Crawford has served as a member of our Board. In 2003, Mr. Crawford founded PTV Healthcare Capital, a venture capital and private equity firm specializing in the healthcare and life sciences industries, and has served as Managing Director since its founding. Mr. Crawford holds a B.A. in History and an M.B.A. from Wake Forest University. We believe Mr. Crawford's qualifications to serve on our Board include his extensive experience in venture capital and the medical technologies industry.

William McClellan

Mr. William D. McClellan, Jr. Since May 2014, Mr. McClellan has served as a member of our Board. Since January 2018, Mr. McClellan has served as the Chief Financial Officer of Aerin Medical, Inc. Since April 2016, Mr. McClellan has served as a financial management consultant to healthcare and life sciences companies, serving as the managing member of Goodwater Consulting, LLC. From June 2004 until June 2016, Mr. McClellan was the Chief Financial Officer and Executive Vice President, Finance at On-X Life Technologies Holdings, Inc. He currently serves on the Board of Directors of Reata Pharmaceuticals, Inc., a publicly-traded company, and chairs its audit committee. Mr. McClellan received a B.B.A. in accounting from Abilene Christian University and is a Certified Public Accountant. We believe that Mr. McClellan is qualified to serve on our Board due to his extensive experience in finance and accounting roles in the healthcare and life sciences industry and in serving as a certified public accountant at a large accounting firm.

R. Kent McGaughy

Mr. R. Kent McGaughy, Jr. is the independent director of the company. Since January 2012, Mr. McGaughy has served as a member of our Board. Since 2003, Mr. McGaughy has served as a Managing Director at CPMG, Inc. where he is a founding stockholder. Mr. McGaughy currently serves on the Board of Directors of Reata Pharmaceuticals Inc., a publicly traded company. He holds a B.A. from The University of Texas (Plan II Honors, Summa Cum Laude and is a member of Phi Beta Kappa) and an M.B.A. from Harvard Business School. We believe Mr. McGaughy's qualifications to serve on our Board include his extensive leadership and executive experience in the financial services industry and his financial expertise.

David Pacitti

Mr. David C. Pacitti. is the independent director of the company ,Since November 2017. Since 2015, Mr. Pacitti has served as the President and CEO of Siemens Medical Solutions, Head of the Americas - Siemens Healthineers where he is responsible for Siemen’s multi-billion dollar commercial operations in the America's. From February 2006 to October 2015, Mr. Pacitti was with Abbott Vascular in a variety of commercial leadership roles. Mr. Pacitti received a B.A. in Economics from Villanova University. We believe Mr. Pacitti’s qualifications to serve on our Board include his extensive commercial expertise and medical device leadership experience

Bruce Robertson

Mr. Bruce Robertson, Ph.D is the independent director of the company. Since February 2008, Dr. Robertson has served as a member of our Board. Since 2005, Dr. Robertson has served as Managing Director of H.I.G. Capital, LLC, a global private equity and investment firm. Dr. Robertson holds a B.S.E. in Chemical Engineering and B.A. in Mathematics from the University of Pennsylvania, an M.B.A. from Harvard Business School, and a Ph.D. in Chemical Engineering from the University of Delaware. We believe Dr. Robertson's qualifications to serve on our Board include his medical and research backgrounds and his extensive experience in venture capital and the medical technologies industry.